CT-202

N/A

Report date: 2026/04/23 20:00:25
First In Class

Base Information

Drug NameCT-202
Drug Alias NameNectin-4/CD3 T Cell Engaging Bispecific AntibodyCT-202BA3362
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-NECTIN4Anti-CD3CD3 T-cell engagers
TargetsNectin-4T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioAtla Inc
China Registration ClassN/A

Develop Information

Active CompaniesContext Therapeutics IncBioAtla Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A